Samyang Biopharm

At a glance

Samyang Biopharm filed 30 disclosures in the last 12 months, including 6 insider and 4 5% holder. The most recent key filing was on Aug 10: A major holder's stake rose from 46.39% to 46.41%.

Revenue for 2025 was ₩28.6B. Operating margin was 9.4%. Debt was 45% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩67B and operating profit of ₩2.1B.

The 2025 annual report lists 407 employees with an average tenure of 9.1 years and average pay of ₩79.4M, #458 of 2,191 listed companies by average pay. Its 5 directors and auditors were paid ₩25M each on average. It paid no cash dividend for 2025. 김 원 and related parties held 46.39% at year end.

Of 4 recent 5%+ holder reports, 2 raised and 0 cut a stake; the largest stake reported was 46.41% on Aug 10.

From the 2025 annual report

Staff: 407 (268 men, 139 women), of whom 36 on fixed-term contracts. Total pay for the year: ₩31.8B. Directors and auditors: 5, paid ₩123M in total.

No cash dividend was paid for 2025.

Largest shareholder

김 원 holds 5.80%; with 28 related parties the group holds 46.39% of common shares at year end.

Auditor: 한영회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports